沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效  

Clinical efficacy of salmetro ticasone powder inhalant in the treatment of bronchial asthma

作　　者：李丽[1] LI Li(th Hospital,Joint Logistic Support Force of PLA,Dalian,Liaoning,116000,China)

机构地区：[1]中国人民解放军联勤保障部队第九六七医院,辽宁大连116000

出　　处：《当代医学》2022年第29期93-95,共3页Contemporary Medicine

摘　　要：目的探讨沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效。方法选取2019年4月至2021年3月于本院就诊治疗的76例支气管哮喘患者作为研究对象,采用随机抽签法分为对照组和研究组,每组38例。对照组采用常规治疗,研究组采用沙美特罗替卡松粉吸入剂治疗,比较两组临床疗效、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰值流速(PEF)]及药物不良反应(皮疹、声音嘶哑、咽部不适)发生情况。结果研究组治疗总有效率为94.74%,高于对照组的78.95%,差异有统计学意义(P<0.05);研究组FVC[(2.74±0.23)L]、FEV1[(1.55±0.21)L]大于对照组的[(2.57±0.11)L、(1.39±0.20)L],研究组PEF[(279.51±80.45)L/min]高于对照组[(243.18±74.26)L/min],差异有统计学意义(P<0.05);研究组药物不良反应发生率为5.26%,低于对照组的23.68%,差异有统计学意义(P<0.05)。结论沙美特罗替卡松粉吸入剂治疗支气管哮喘效果显著,可改善患者肺功能,减少不良反应发生率,值得临床推广应用。Objective To investigate the clinical efficacy of salmetro ticasone powder inhalant in in the treatment of bronchial asthma.Methods A total of 76 patients with bronchial asthma treated in our hospital from April 2019 to March 2021 were selected as research subjects,and they were divided into control group and study group by random drawing method,with 38 cases in each group.The control group was treated with conventional treatment,and the study group was treated with salmeterol ticasone powder inhalant.The clinical efficacy,pulmonary function indexes(forced vital capacity[FVC],forced expiratory volume in one second[FEV1],peak expiratory flow[PEF])and the occurrence of adverse drug reactions(rash,hoatiess,pharyngeal discomfort)were compared between the two groups.Results The total effective rate was 94.74%in the study group,which was higher than 78.95%in the control group,and the difference was statistically significant(P<0.05).The FVC([2.74±0.23]L)and FEV1([1.55±0.21]L)in the study group were biger than those in the control group([2.57±0.11]L,[1.39±0.20]L),and the PEF in the study group was([279.51±80.45]L/min),which was higher than([243.18±74.26]L/min)in the control group,the difference was statistically significant(P<0.05).The incidence of ADR in the study group was 5.26%,lower than 23.68%in the control group,and the difference was statistically significant(P<0.05).Conclusion The use of salmeterol ticasone powder inhalant in the treatment of bronchial asthma has significant effect,can improve the lung function of patients,reduce the incidence of adverse reactions,worthy of clinical application.

关 键 词：支气管哮喘 肺功能 临床疗效 不良反应 沙美特罗替卡松粉吸入剂 

分 类 号：R562.25[医药卫生—呼吸系统]